The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

July 2-8, 1993
The Given Institute
Aspen, Colorado

The Given Institute
Aspen, Colorado

ORGANIZERS

STEPHEN H. FRIEND
Massachusetts General Hospital
Charlestown, MA

L. MICHAEL GLODÉ
University of Colorado School
of Medicine
Denver, CO

• Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology such as gene therapy, oncogenes and growth factors, tumor suppressor genes, fusion proteins, genetic mutations, antisense, metastasis, and drug resistance.

• Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.

• A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.

• Financial support for participants who are physicians in training or oncology fellows.

• Category I CME credits through the University of Colorado School of Medicine.

Faculty

Lectures

OWEN N. WITTE/ Los Angeles, CA
KENNETH W. CULVER/ Bethesda, MD
ANDRÉ BERNARDS/ Charlestown, MA
HAROLD L. MOSES/ Nashville, TN
ADI F. GAZDAR/ Dallas, TX
CORI GORMAN/ San Francisco, CA

DAVID E. PETERSON/ Denver, CO
CRAIG TUERK/ Boulder, CO
EMMETT SCHMIDT/ Charlestown, MA
STEPHEN H. FRIEND/ Charlestown, MA
ERIC R. FEARON/ Baltimore, MD
L. MICHAEL GLODÉ/ Denver, CO

PATRICIA S. STEEG/ Bethesda, MD
MARCE. L. LIPPMAN/ Washington, DC
MASAAKI TERADA/ Tokyo, Japan
WILLIAM S. DALTON/ Tucson, AZ
JOHN R. MURPHY/ Boston, MA
JACKIE LEES/ Charlestown, MA

Additional Speakers to be Announced

Laboratory Rotations

ANNE KALLIONIEMI and OLLI-P. KALLIONIEMI/ San Francisco, CA. "Practical Molecular Cytogenetics."
MARK S. BOGUSKI/ Bethesda, MD. "Computer Searching in Molecular Biology."
IAN H. MAXWELL and L. MICHAEL GLODÉ/ Denver, CO. "Polymerase Chain Reaction Technology."
CORI M. GORMAN/ San Francisco, CA. "Gene Expression Systems."

Application Deadline April 30, 1993

For further information, contact
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS

An Important Educational Opportunity for
Predoctoral and Postdoctoral Fellows
Contemplating Careers in Basic Cancer Research

HISTOPATHOBIOLOGY OF NEOPLASIA

The Edward A. Smuckler Memorial Workshop
Supported by a Generous Grant from the National Cancer Institute

Keystone Conference Center
Keystone, Colorado
June 20 - June 27, 1993

- Intensive training in the histopathology and biology of neoplasia.
- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists.
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators.
- Extensive written course materials that will serve as valuable references in the future.
- Full funding of participants' lodging and subsistence expenses during the workshop.

LABORATORY AND LECTURING FACULTY

John H. Lehman*, Albany College of Medicine, Albany, NY, Course Director
Stephen Baird*, VA Medical Center, San Diego, CA
Helen Feiner, New York University School of Medicine, New York, NY
Michael W. Lieberman*, Baylor College of Medicine, Houston, TX
Robert Low, University of Colorado School of Medicine, Denver, CO
Gary Miller*, University of Colorado School of Medicine, Denver, CO
Harold L. Moses, Vanderbilt University School of Medicine, Nashville, TN
Sharon B. Murphy, Children's Hospital, Chicago, IL
Garth L. Nicolson, UT-M. D. Anderson Cancer Ctr., Houston, TX
G. Barry Pierce, University of Colorado School of Medicine, Denver, CO.
Michael Prystowsky, University of Pennsylvania School of Medicine, Philadelphia, PA
Stewart Sell, University of Texas Medical School, Houston, TX
Saraswati Sukumar, The Salk Institute, La Jolla, CA
Frederick Waldman, University of California, San Francisco, CA
Sandra R. Wolman*, Harper Hospital, Detroit, MI

*Member of the Workshop Executive Committee

APPLICATION DEADLINE: APRIL 30, 1993

Further Information: American Association for Cancer Research • Public Ledger Building
620 Chestnut Street • Suite 816 • Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SCIENTIFIC CONFERENCES: 1993-1994

APRIL 13-17, 1993
Genetic Control of Cell Growth
Laureates Conference
General Motors Cancer Research Foundation
Chairpersons: Leland H. Hartwell, Seattle, WA; Peter K. Vogt, Los Angeles, CA; George F. Vande Woude, Frederick, MD
San Luis Hotel, Galveston, TX

MAY 19-22, 1993
84th Annual Meeting
Chairperson: Michael B. Sporn, Bethesda, MD
Orange County Convention Center, Orlando, FL

OCTOBER 17-21, 1993
Cell Death and Cancer
Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993
Molecular Approaches to Cancer Immunotherapy
Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993
Interactions of Cancer Susceptibility Genes and Environmental Carcinogenesis
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederick P. Li, Boston, MA, and Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993
Cell Signalling and Cancer Treatment
Joint Meeting with British Association for Cancer Research and European Organisation for Research and Treatment of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ; Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994
Risk Assessment in Environmental Carcinogenesis
Chairpersons: Philip C. Hanawalt, Stanford, CA; James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler, B.C., Canada

JANUARY 31-FEBRUARY 5, 1994
Molecular Genetics of Progression and Metastasis
Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994
Genomic Instability and Cancer
Chairpersons: Thea D. Tlsty and Lawrence A. Loeb
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994
Growth Factors, Development, and Cancer
Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses and Bernd Groner
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994
85th Annual Meeting
Chairperson: Karen S.H. Antman, Boston, MA
Moscone Center, San Francisco, CA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
The Pezcoller Foundation, Trento, Italy

The Pezcoller Foundation is a non-profit organization created in 1979 by Prof. Alessio Pezcoller, who was the chief Surgeon of the Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research. To this end, it annually sponsors a symposium at the cutting edge of basic research and biennially awards a prize for fundamental discoveries in the aetiology, pathogenesis, treatment or natural history of a disease; the winner is selected by an International Committee chaired by Prof. U. Veronesi, European School of Oncology. The symposia are structured to favor intensive discussions among participants leading to the development of new ideas and perspective. The topics are chosen by an International Advisory Committee composed of: E. Mihich, Chairman (Buffalo), G. Bernardi (Trento), C. Croce (Philadelphia), G. Della Porta (Milan), V. DeVita (New York), G. Lenaz (Bologna), A. Levine (Princeton), D. Livingston (Boston), P. Schlechter (Trento), E. Solomon (London), T. Taniguchi (Osaka), F. Zueli (Trento).

Fifth Pezcoller Symposium, June 9-11, 1993, Trento, Italy: Apoptosis

Co-Chairmen: E. Mihich and R. Schimke
Program Committee: Drs. E. Mihich (Chairman), M. Bishop, A. Levine, D. Livingston, R. Schimke

June 9, AM, Session I, Co-Chairmen: E. Mihich and P. Amati
Robert Horvitz Genetic control of programmed cell death in the nematode Caenorhabditis elegans
David Papamasteris Inherited retinal degenerations: Is apoptosis involved?

June 9, PM, Session II, Co-Chairmen: A. Levine and C. Riccardi
Moshe Oren The involvement of p53 in apoptosis
Eileen White Regulation of apoptosis by the transforming gene products of adenovirus
Gerard Evan Coupled control of cell proliferation and death by the c-Myc protein
John Cleveland Regulatory mechanisms of apoptosis in myeloid progenitor cells

June 10, AM, Session III, Co-Chairmen: D. Livingston and G. Bellomo
Pierluigi Nicotera Ion signalling in apoptosis
Michael Kastan Molecular controls of cell cycle progression following DNA damage: roles of p53 and ataxia-telangiectasia gene products
John Isaacs Neither DNA synthesis nor p53 function are required for programmed cell death of androgen dependent prostatic cell induced by androgen ablation

June 11, AM, Session IV, Co-Chairmen: S. Schlossman and M. Fried
David Hockenberg The bcl-2 gene and cell death: insights into the mechanism of apoptosis
Jonathan Ashwell Steroid regulation of activation-induced T cell apoptosis
Tadatsugu Taniguchi Transcription factors IRF-1 and IRF-2; A link between the interferon system and cell growth control

Douglas Green Oncogene interactions in apoptosis

June 11, PM, Session V, Co-Chairmen: R. Schimke and M. D'Incalci
Steve Shenwood Disturbances in cell cycle progression and the induction of apoptosis in cultured cells
Peter Krammer APO-1 mediated apoptosis at the crossroad of lymphoproliferation and autoimmunity
Alan Eastman Endonucleases associated with apoptosis

Symposium Discussants: Terry Grodzieker, Domenico Delia

For further information on the Fifth Symposium, please contact Ms. Ann Toscani, Roswell Park Cancer Institute, Buffalo, NY 14263, USA (Tel: 716-845-8225; Fax: 716-845-8857), and for local arrangements, Mr. Giorgio Pederzolli, The Pezcoller Foundation, Trento, Italy (Tel: 39-461-211265; Fax: 39-461-980350).
INTERACTIONS OF CANCER SUSCEPTIBILITY GENES AND ENVIRONMENTAL CARCINOGENS

Joint Meeting Organized by the American Association for Cancer Research (AACR) and the International Agency for Research on Cancer (IARC)

November 9-13, 1993
Lyon, France

CONFERENCE CHAIRPERSONS
Frederick P. Li / Boston, USA
Ruggero Montesano / Lyon, France

SCIENTIFIC PROGRAM

Introductory Lectures
Curtis C. Harris / Bethesda, USA
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
Manfred F. Rajewsky / Essen, Germany

Genetic Instability
Kari K. Alitalo / Helsinki, Finland
T. Heidmann / Paris, France
Thea D. Tlsty / Chapel Hill, USA

Experimental Models of Genetic Susceptibility
J. Carl Barrett / Research Triangle Park, USA
Henry C. Pitot / Madison, USA
Bernard M. Mechler / Heidelberg, Germany

DNA Damage and Repair
Dirk Bootsma / Rotterdam, The Netherlands
John M. Essigmann / Cambridge, USA
Mutsuo Sekiguchi / Fukuoka, Japan

Mechanisms of Transgenerational Carcinogenesis
Carmen Sapienza / La Jolla, USA
Ulrike Wintersberger / Vienna, Austria
David Malkin / Toronto, Canada
Christopher J. Kemp / Glasgow, Scotland

Human Cancers
Frederick P. Li / Boston, USA
Valerie Beral / Oxford, England
Bruce A. J. Ponder / Cambridge, England
Neil E. Caporaso / Bethesda, USA
Gilbert M. Lenoir / Lyon, France

Markers of Individual Exposure
Ruggero Montesano / Lyon, France
Peter A. Cerutti / Epalinges, Switzerland

Opportunities for Prevention
I. Bernard Weinstein / New York, USA

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
Featured on this issue's cover is Hilary Koprowski, one of the most distinguished scientists in contemporary medicine. Over the past 43 years, in an astonishingly active and productive career, he has achieved a number of remarkable experimental and clinical advances involving various aspects of animal and human immunology and virology.

Dr. Koprowski was born in Warsaw, Poland, and received the M.D. in 1939 from the University of Warsaw. He spent the next five years in the Yellow Fever Research Service of the Rockefeller Foundation in Rio de Janeiro, Brazil. In 1944, he joined the Lederle Laboratories of the American Cyanamid Company, working in its Section of Viral and Rickettsial Research, first as a Research Associate and then as Assistant Director. He remained with Lederle Laboratories until 1957, when he was appointed Director and Institute Professor of the Wistar Institute of Anatomy and Biology in Philadelphia. He has also held adjunct appointments at the nearby University of Pennsylvania where he has served as the Wistar Professor of Research Medicine and as Professor of Microbiology. At present, Dr. Koprowski is Institute Professor at the Wistar Institute, and he continues to conduct research as a Professor in the Department of Microbiology and Immunology at Thomas Jefferson University.

In a few years, through strong leadership and remarkable vigor, Dr. Koprowski transformed the Wistar Institute from what was essentially a museum of mammalian anatomy, housed in an old-fashioned building of 62,600 square feet, into a large and thriving institution that now occupies 167,321 square feet. Today, the Institute boasts a roster of world-class scientists who work on the cutting edge of research on cancer and related medical problems.

During the 1970s, Dr. Koprowski was quick to recognize the potential of monoclonal antibodies (MAbs) in the diagnosis and treatment of cancer. There followed an intensive campaign to fully explore this potential. In 1977, Dr. Koprowski and his colleagues injected a group of mice with cells derived from human cancer. The spleens were removed from the inoculated mice, and a single-cell suspension was prepared. The cells were then fused with mouse myeloma cells. This procedure gave rise to a cell line that produced the first MAb to react with an antigen(s) expressed by human cancer (melanoma) cells and with colon carcinoma cells.

Shortly after their discovery, two of these antibodies were selected for clinical application. One antibody, reactive with a carbohydrate moiety of sialylated Lewis-A antigen, recognized an antigen found in the blood of patients suffering from gastrointestinal cancers, such as colorectal and pancreatic cancers. This antibody is presently used by clinicians for diagnostic purposes in many countries of the world. The second antibody to react with a glycoprotein was found, more than a decade ago, to participate in the destruction of human gastrointestinal cancer cells by directing human macrophages to kill the cells. This antibody, 17-1A, has been in clinical use in the immunotherapy of types of human cancer for many years. Although sporadic cures of colon or pancreatic cancers were observed after administration of this antibody, only a recently concluded trial in Germany showed a statistically significant difference in the rates of patient survival and recurrence of malignancy between patients treated with 17-1A and those not treated with this antibody.

In 1984, Dr. Koprowski postulated that a favorable outcome of therapy with MAbs may be related to the development by the patient of a specific antidiotypic response that reflects the mirror image of the tumor antigen. In turn, the presence of antidiotypic responses induces the formation in the patient of an antibody (Ab3) that may react with and destroy the patient's tumor.

Since the early discoveries, progress in the immunotherapy of human cancer has advanced rapidly under Dr. Koprowski's direction; MAbs reacting with melanoma, breast cancer, and growth factors have been developed, and some are already in use in the clinic. Human cancer antigens have been cloned, sequenced, and incorporated into expression vectors. Thus, three arms of immunotherapy are presently available: MAbs; antidiotypic; and cancer antigens acting as vaccines (Cole, J. S., II, and Gruber, J. Commentary: progress and prospects for human cancer vaccines. J. Natl. Cancer Inst., 84: No. 1, January 1, 1992). In light of his belief that the success of immunotherapy is related to its application in patients with minimal tumor burden, Dr. Koprowski has worked actively with his German colleagues, G. Schlimok and G. Riehmuller, to search for cancer cells within the human body in such sheltering sites as bone marrow. Their studies in the area of cancer immunology are summarized in the following articles: Proc. Natl. Acad. Sci. USA, 7: 3532–3546, 1990; Proc. Natl. Acad. Sci. USA, 8: 6833–6837, 1990; and J. Natl. Cancer Inst., 84: 18–23, 1992.

Dr. Koprowski is a member of the National Academy of Sciences and the American Academy of Arts and Sciences as well as a foreign member of the Yugoslav and Polish Academies of Sciences. He has been an active member of the AACR, serving on the Board of Directors and on the Membership and Program Committees.

Dr. Koprowski's interests extend beyond the field of cancer research. He was and is active in research on chronic neurological diseases, and he is the world authority on rabies. He is the author or coauthor of over 800 scientific papers. He has been both a member of and a consultant to scientific organizations worldwide, and he has received many honorary degrees and awards. Moreover, Dr. Koprowski is an accomplished pianist, having graduated from St. Cecilia Academy in Rome.

Sidney Weinhouse